

Resource Summary Report

Generated by [NIF](#) on Sep 16, 2026

Mel JuSo

RRID:CVCL_1403

Type: Cell Line

Proper Citation

RRID:CVCL_1403

Cell Line Information

URL: https://web.expasy.org/cellosaurus/CVCL_1403

Proper Citation: RRID:CVCL_1403

Description: Cell line Mel JuSo is a Cancer cell line with a species of origin Homo sapiens (Human)

Sex: Female

Disease: Cutaneous melanoma

Defining Citation: [PMID:2174414](#), [PMID:6895502](#), [PMID:9598804](#), [PMID:10766161](#), [PMID:11668190](#), [PMID:15009714](#), [PMID:18698037](#), [PMID:20164919](#), [PMID:22460905](#), [PMID:25877200](#), [PMID:26589293](#), [PMID:27397505](#), [PMID:30894373](#), [PMID:31068700](#), [PMID:31978347](#), [PMID:35839778](#)

Comments: Population: Caucasian., Part of: COSMIC cell lines project., Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).

Category: Cancer cell line

Organism: Homo sapiens (Human)

Name: Mel JuSo

Synonyms: MEL-Juso, MEL-JUSO, Mel-Juso, Mel Juso, MelJuSo, MELJUSO, JuSo

Cross References: BTO:BTO_0001588, CLO:CLO_0007676, EFO:EFO_0022434, EFO:EFO_0022720, CLDB:cl3440, ArrayExpress:E-MTAB-783, ArrayExpress:E-MTAB-2770, ArrayExpress:E-MTAB-3610, BioGRID_ORCS_Cell_line:548, BioSample:SAMN03471884, BioSample:SAMN10988249, cancercellines:CVCL_1403, Cell_Model_Passport:SIDM00336, ChEMBL-Cells:ChEMBL3308761, ChEMBL-Targets:ChEMBL1075501, CLS:300282, Cosmic:706091, Cosmic:888060, Cosmic:888835, Cosmic:897474, Cosmic:908125, Cosmic:1020272, Cosmic:1022285,

Cosmic:1459306, Cosmic:1995505, Cosmic-CLP:908125, DepMap:ACH-000881, DSMZ:ACC-74, DSMZCellDive:ACC-74, EGA:EGAS00001000978, GDSC:908125, GEO:GSM887309, GEO:GSM888385, GEO:GSM1374670, GEO:GSM1670095, IARC_TP53:21493, LiGeA:CCL_674, LINCS_LDP:LCL-1252, PharmacDB:MELJUSO_915_2019, PRIDE:PXD011899, PRIDE:PXD019519, PRIDE:PXD021877, PRIDE:PXD030304, Progenetix:CVCL_1403, PubChem_Cell_line:CVCL_1403, Wikidata:Q54905064

ID: CVCL_1403

Record Creation Time: 20220427T220801+0000

Record Last Update: 20260913T004844+0000

Ratings and Alerts

No rating or validation information has been found for Mel JuSo.

No alerts have been found for Mel JuSo.

Data and Source Information

Source: [Cellosaurus](#)

Usage and Citation Metrics

We found 26 mentions in open access literature.

Listed below are recent publications. The full list is available at [NIF](#) .

Lörentz S, et al. (2026) SNAT1 (SLC38A1) Is Not the Main Glutamine Transporter in Melanoma, but Controls Metabolism via Glutamine-Dependent Activation of P62 (SQSTM1)/cMYC-Axis. *Cancers*, 18(7).

Gierisch ME, et al. (2026) Mitochondria serve as a holdout compartment for aggregation-prone proteins hindering efficient degradation. *Nature communications*, 17(1).

Chancellor A, et al. (2025) The carbonyl nucleobase adduct M3Ad is a potent antigen for adaptive polyclonal MR1-restricted T cells. *Immunity*, 58(2), 431.

Boucher J, et al. (2025) CDK12 inhibition reveals melanoma dependence on the RUNX1/CBF? complex for genomic stability. *Cell reports*, 44(11), 116495.

Prota G, et al. (2025) Mitochondria regulate MR1 protein expression and produce self-metabolites that activate MR1-restricted T cells. *Proceedings of the National Academy of Sciences of the United States of America*, 122(20), e2418525122.

Tröster BC, et al. (2025) Emerging role of ARHGAP29 in melanoma cell phenotype switching. *Molecular oncology*.

Saamarthy K, et al. (2025) An optimised Bcl-3 inhibitor for melanoma treatment. British journal of pharmacology, 182(11), 2426.

Blundell SV, et al. (2025) Mammalian and bacterial adaptors function as co-disinhibitory pairs to activate the E3 ubiquitin ligase WWP2. The Journal of biological chemistry, 301(12), 110847.

Schoufour TAW, et al. (2024) CRISPR-Cas9 screening reveals a distinct class of MHC-I binders with precise HLA-peptide recognition. iScience, 27(6), 110120.

Devitt L, et al. (2024) NRN1 interacts with Notch to increase oncogenic STAT3 signaling in melanoma. Cell communication and signaling : CCS, 22(1), 256.

Qiao X, et al. (2024) Diversifying the anthracycline class of anti-cancer drugs identifies aclarubicin for superior survival of acute myeloid leukemia patients. Molecular cancer, 23(1), 120.

Jongsma MLM, et al. (2024) Systems mapping of bidirectional endosomal transport through the crowded cell. Current biology : CB, 34(19), 4476.

Meißgeier T, et al. (2024) Splicing control by PHF5A is crucial for melanoma cell survival. Cell proliferation, e13741.

van Vliet AA, et al. (2023) Early TRAIL-engagement elicits potent multimodal targeting of melanoma by CD34+ progenitor cell-derived NK cells. iScience, 26(7), 107078.

Díaz-Anaya AM, et al. (2023) The ? Isoform of Human ATP-Binding Cassette B5 Transporter, ABCB5?, Localizes to the Endoplasmic Reticulum. International journal of molecular sciences, 24(21).

Martín-Vega A, et al. (2023) Scaffold coupling: ERK activation by trans-phosphorylation across different scaffold protein species. Science advances, 9(7), eadd7969.

Zimmermann T, et al. (2023) Cold Atmospheric Plasma Triggers Apoptosis via the Unfolded Protein Response in Melanoma Cells. Cancers, 15(4).

Xu S, et al. (2023) Cytosolic stress granules relieve the ubiquitin-proteasome system in the nuclear compartment. The EMBO journal, 42(3), e111802.

Linck-Paulus L, et al. (2022) A previously unknown Argonaute 2 variant positively modulates the viability of melanoma cells. Cellular and molecular life sciences : CMLS, 79(9), 475.

Linck-Paulus L, et al. (2021) Learning from Embryogenesis-A Comparative Expression Analysis in Melanoblast Differentiation and Tumorigenesis Reveals miRNAs Driving Melanoma Development. Journal of clinical medicine, 10(11).